Yunnan Botanee Bio-Technology GroupLTD Future Growth
Future criteria checks 4/6
Yunnan Botanee Bio-Technology GroupLTD is forecast to grow earnings and revenue by 29.3% and 13.8% per annum respectively. EPS is expected to grow by 29.2% per annum. Return on equity is forecast to be 14.6% in 3 years.
Key information
29.3%
Earnings growth rate
29.2%
EPS growth rate
Personal Products earnings growth | 25.9% |
Revenue growth rate | 13.8% |
Future return on equity | 14.6% |
Analyst coverage | Good |
Last updated | 29 Jan 2025 |
Recent future growth updates
Recent updates
Fewer Investors Than Expected Jumping On Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)
Jan 01Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders
Nov 02Is Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Trading At A 39% Discount?
Oct 19The Market Lifts Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Shares 26% But It Can Do More
Sep 27Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?
Sep 25Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Will Pay A Smaller Dividend Than Last Year
Jun 03A Look At The Fair Value Of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)
May 24Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 02Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet
Feb 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8,318 | 1,168 | 1,211 | 1,377 | 22 |
12/31/2025 | 7,438 | 1,012 | 990 | 1,040 | 22 |
12/31/2024 | 6,438 | 711 | 1,432 | 900 | 16 |
9/30/2024 | 6,108 | 592 | 117 | 492 | N/A |
6/30/2024 | 5,959 | 791 | 120 | 467 | N/A |
3/31/2024 | 5,756 | 775 | 342 | 649 | N/A |
12/31/2023 | 5,522 | 757 | 336 | 610 | N/A |
9/30/2023 | 5,550 | 1,113 | 554 | 808 | N/A |
6/30/2023 | 5,332 | 1,106 | 550 | 843 | N/A |
3/31/2023 | 5,069 | 1,064 | 434 | 740 | N/A |
1/1/2023 | 5,014 | 1,051 | 416 | 769 | N/A |
9/30/2022 | 4,805 | 1,025 | 532 | 891 | N/A |
6/30/2022 | 4,660 | 993 | 637 | 999 | N/A |
3/31/2022 | 4,323 | 930 | 601 | 935 | N/A |
1/1/2022 | 4,022 | 863 | 882 | 1,153 | N/A |
9/30/2021 | 3,332 | 683 | 518 | 721 | N/A |
6/30/2021 | 3,107 | 648 | 570 | 702 | N/A |
3/31/2021 | 2,825 | 568 | 438 | 546 | N/A |
12/31/2020 | 2,636 | 544 | 342 | 431 | N/A |
12/31/2019 | 1,944 | 412 | 454 | 515 | N/A |
12/31/2018 | 1,240 | 261 | 71 | 102 | N/A |
12/31/2017 | 798 | 154 | N/A | 202 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300957's forecast earnings growth (29.3% per year) is above the savings rate (2.8%).
Earnings vs Market: 300957's earnings (29.3% per year) are forecast to grow faster than the CN market (25.1% per year).
High Growth Earnings: 300957's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300957's revenue (13.8% per year) is forecast to grow faster than the CN market (13.3% per year).
High Growth Revenue: 300957's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300957's Return on Equity is forecast to be low in 3 years time (14.6%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/04 02:52 |
End of Day Share Price | 2025/01/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Yunnan Botanee Bio-Technology Group Co.LTD is covered by 41 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Xiyue Zhang | Chasing Securities |
Jian Jun Zou | Chasing Securities |
Zhuonan Xu | China International Capital Corporation Limited |